BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0022
0.00 (0.00%)
May 22, 2026, 5:02 PM CET
Market Cap1.44M +29.4%
Revenue (ttm)-2.39M -69.6%
Net Income-4.00M
EPS-0.01
Shares Out652.86M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,984,211
Average Volume1,743,981
Open0.0022
Previous Close0.0022
Day's Range0.0020 - 0.0022
52-Week Range0.0016 - 0.0032
Beta-1.60
RSI48.86
Earnings DateSep 7, 2026

About BioSenic

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult ti... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jean-Luc Vandebroek
Employees 7
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements